A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.

Phenylacetate has recently been shown to suppress tumor growth and promote differentiation in experimental models. A phase I trial of phenylacetate was conducted in 17 patients with advanced solid tumors. Each patient received a single i.v. bolus dose followed by a 14-day continuous i.v. infusion of the drug. Twenty-one cycles of therapy were administered at four dose levels, achieved by increasing the rate of the continuous i.v. infusion. Phenylacetate displayed nonlinear pharmacokinetics [Km = 105.1 +/- 44.5 (SD) microgram/ml, Vmax = 24.1 +/- 5.2 mg/kg/h and Vd = 19.2 +/- 3.3 L]. There was also evidence for induction of drug clearance. Ninety-nine % of phenylacetate elimination was accounted for by conversion to phenylacetylglutamine, which was excreted in the urine. Continuous i.v. infusion rates resulting in serum phenylacetate concentrations exceeding Km often resulted in rapid drug accumulation and dose-limiting toxicity, which consisted of reversible central nervous system depression, preceded by emesis. Three of nine patients with metastatic, hormone-refractory prostate cancer maintained stable prostatic specific antigen levels for more than 2 months; another had less bone pain. One of six patients with glioblastoma multiforme, whose steroid dosage has remained unchanged for the duration of therapy, has sustained functional improvement for more than 9 months. The use of adaptive control with feedback for the dosing of each patient enabled us to safely maintain stable phenylacetate concentrations up to the range of 200-300 micrograms/ml, which resulted in clinical improvement in some patients with advanced disease.

[1]  Z. Ram,et al.  Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. , 1994, Cancer research.

[2]  S. Shack,et al.  Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. , 1993, The Journal of clinical investigation.

[3]  D. Samid,et al.  Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. , 1992, Blood.

[4]  D. Samid,et al.  Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. , 1992, The New England journal of medicine.

[5]  S. Shack,et al.  Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. , 1992, Cancer research.

[6]  O. Simell,et al.  Waste Nitrogen Excretion Via Amino Acid Acylation: Benzoate and Phenylacetate in Lysinuric Protein Intolerance , 1986, Pediatric Research.

[7]  C. Mendenhall,et al.  A new therapy for portal systemic encephalopathy. , 1986, The American journal of gastroenterology.

[8]  S. Brusilow,et al.  TRANSIENT IDIOPATHIC HYPERAMMONAEMIA IN ADULTS , 1985, The Lancet.

[9]  S. Brusilow,et al.  Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. , 1984, The New England journal of medicine.

[10]  A. Lees,et al.  Phenylacetic acid in human body fluids: high correlation between plasma and cerebrospinal fluid concentration values. , 1982, Journal of neurology, neurosurgery, and psychiatry.

[11]  M. James,et al.  The conjugation of phenylacetic acid in man, sub-human primates and some non-primate species , 1972, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[12]  S. Shapiro,et al.  An Analysis of Variance Test for Normality (Complete Samples) , 1965 .

[13]  A. Meister,et al.  Synthesis of phenylacetylglutamine by human tissue. , 1957, The Journal of biological chemistry.

[14]  F. Wilcoxon Individual Comparisons by Ranking Methods , 1945 .

[15]  S. Burzynski,et al.  Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. , 1990, Drugs under experimental and clinical research.

[16]  D. M. Ellis,et al.  Applied Regression Analysis , 1968 .